Insider · CIK 0001333277

Quinlan Paul T

Reports to the SEC for 3 companies · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001333277

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-20	ORKAOruka Therapeutics, Inc. · Employee Warrant (right to buy)M Exercise/Conversion	General Counsel	MExercise/Conversion	−9,000 sh	—	—	70,996
2026-10-20	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−3,000 sh	$79.49	−$238K	29,995
2026-10-20	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−4,100 sh	$78.79	−$323K	32,995
2026-10-20	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−1,000 sh	$77.20	−$77.2K	37,095
2026-10-20	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−500 sh	$76.12	−$38.1K	38,095
2026-10-20	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−400 sh	$74.90	−$30K	38,595
2026-10-20	ORKAOruka Therapeutics, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+9,000 sh	$7.80	+$70.2K	38,995
2026-09-21	ORKAOruka Therapeutics, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+10K sh	$7.80	+$78K	39,995
2026-09-21	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−2,900 sh	$92.37	−$268K	37,095
2026-09-21	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−3,832 sh	$93.32	−$358K	33,263
2026-09-21	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−601 sh	$94.44	−$56.8K	32,662
2026-09-21	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−2,667 sh	$95.31	−$254K	29,995
2026-09-21	ORKAOruka Therapeutics, Inc. · Employee Warrant (right to buy)M Exercise/Conversion	General Counsel	MExercise/Conversion	−10K sh	—	—	79,996
2026-09-15	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−1,039 sh	$95.71	−$99.4K	29,995
2026-08-14	ORKAOruka Therapeutics, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+10K sh	$7.80	+$78K	41,034
2026-08-14	ORKAOruka Therapeutics, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+42K sh	$12.50	+$525K	83,034
2026-08-14	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−3,630 sh	$106.05	−$385K	79,404
2026-08-14	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−10.4K sh	$107.14	−$1.12M	68,970
2026-08-14	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−14.7K sh	$107.97	−$1.59M	54,274
2026-08-14	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−10.2K sh	$109.11	−$1.11M	44,074
2026-08-14	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−9,193 sh	$110.00	−$1.01M	34,881
2026-08-14	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−3,847 sh	$111.14	−$428K	31,034
2026-08-14	ORKAOruka Therapeutics, Inc. · Employee Warrant (right to buy)M Exercise/Conversion	General Counsel	MExercise/Conversion	−10K sh	—	—	89,996
2026-08-14	ORKAOruka Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	General Counsel	MExercise/Conversion	−42K sh	—	—	120,500
2026-06-15	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−733 sh	$69.69	−$51.1K	31,034
2026-03-16	ORKAOruka Therapeutics, Inc.S Sale	General Counsel	SSale	−733 sh	$41.30	−$30.3K	31,767
2026-01-23	ORKAOruka Therapeutics, Inc.A Award	General Counsel	AAward	+32.5K sh	—	—	32,500
2026-01-23	ORKAOruka Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	General Counsel	AAward	+130K sh	—	—	130,000
2025-01-22	ORKAOruka Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	General Counsel	AAward	+163K sh	—	—	162,500
2024-03-22	CymaBay Therapeutics, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−41.8K sh	—	—	0
2024-03-22	CymaBay Therapeutics, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−28.4K sh	—	—	0
2024-03-22	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−233K sh	—	—	0
2024-03-22	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−22.2K sh	—	—	0
2024-03-22	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−107K sh	—	—	0
2024-03-22	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−215K sh	—	—	0
2024-03-22	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−106K sh	—	—	0
2024-03-13	CymaBay Therapeutics, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+41.8K sh	$7.89	+$330K	70,262
2024-03-13	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)M Exercise/Conversion	General Counsel	MExercise/Conversion	−41.8K sh	—	—	8,872
2024-01-24	CymaBay Therapeutics, Inc.A Award	General Counsel	AAward	+28.4K sh	—	—	28,438
2024-01-24	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)A Award	General Counsel	AAward	+106K sh	—	—	105,625
2024-01-16	CymaBay Therapeutics, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+5,000 sh	$2.94	+$14.7K	5,000
2024-01-16	CymaBay Therapeutics, Inc.S Sale	General Counsel	SSale	−5,000 sh	$23.58	−$118K	0
2024-01-16	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)M Exercise/Conversion	General Counsel	MExercise/Conversion	−5,000 sh	—	—	107,000
2023-12-15	CymaBay Therapeutics, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+5,000 sh	$2.94	+$14.7K	5,000
2023-12-15	CymaBay Therapeutics, Inc.S Sale	General Counsel	SSale	−5,000 sh	$21.98	−$110K	0
2023-12-15	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)M Exercise/Conversion	General Counsel	MExercise/Conversion	−5,000 sh	—	—	112,000
2023-11-15	CymaBay Therapeutics, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+5,000 sh	$2.94	+$14.7K	5,000
2023-11-15	CymaBay Therapeutics, Inc.S Sale	General Counsel	SSale	−5,000 sh	$17.38	−$86.9K	0
2023-11-15	CymaBay Therapeutics, Inc.Employee Stock Option (right to buy)M Exercise/Conversion	General Counsel	MExercise/Conversion	−5,000 sh	—	—	117,000
2023-10-16	CymaBay Therapeutics, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+5,000 sh	$2.94	+$14.7K	5,000

Recent filings

Accepted (ET)
Oct 204
Quinlan Paul T0000907654-26-000110
SEC(opens sec.gov)
Sep 214
Quinlan Paul T0000907654-26-000100
SEC(opens sec.gov)
Sep 154
Quinlan Paul T0000907654-26-000095
SEC(opens sec.gov)
Aug 144
Quinlan Paul T0000907654-26-000077
SEC(opens sec.gov)

Companies

Address

C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100

MENLO PARK, CA, 94025